13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE 13D Filed 2026-04-23 Event 2026-04-16 Intent: UNCLEAR SEC 0001193125-26-174330 →

BCLS Fund IV Investments, L.P. Kailera Therapeutics, Inc. KLRA

Stake: 17.43% Shares: 22,583,268 CUSIP: 482931102 Class: Common Stock, $0.00001 par value per share
AI Analyst Brief conf: low
BCLS Fund IV (Bain Capital Life Sciences) holds 22.6M shares of Kailera Therapeutics, a clinical-stage biotech, via a 13D — likely reflecting a lead or co-lead investor position from a recent financing round rather than adversarial activism, but the 13D form and two prior activist filings on KLRA in 90 days warrant scrutiny of whether governance or strategic pressure is building.

Item 4 — Purpose of Transaction

The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Adam Koppel, a Partner of BCLSI, is a member of the Issuer's board of directors (the "Board"). The Reporting Person acquired the securities reported herein for investment purposes. In its capacity as a significant stockholder of the Issuer, the Reporting Person intends to take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives. The Reporting Person reviews and intends to continue to review, on an ongoing and continuing basis, their investment in the Issuer. Depending upon the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or sell or otherwise dispose of some or all of their securities of the Issuer. Any transactions that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities avialable to the Reporting Person, tax considerations and other factors.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest
Not in latest FINRA snapshot

Other 13D/G Filings on Kailera Therapeutics, Inc.

FiledFormFilerStakeShares
2026-04-23 SCHEDULE 13D BCPE Perseus Investor, LP 20.27% 26,255,581 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →